These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 36689214

  • 1. Efficacy and Safety of Proposed Biosimilar Natalizumab (PB006) in Patients With Relapsing-Remitting Multiple Sclerosis: The Antelope Phase 3 Randomized Clinical Trial.
    Hemmer B, Wiendl H, Roth K, Wessels H, Höfler J, Hornuss C, Liedert B, Selmaj K.
    JAMA Neurol; 2023 Mar 01; 80(3):298-307. PubMed ID: 36689214
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetic and pharmacodynamic similarity of biosimilar natalizumab (PB006) to its reference medicine: a randomized controlled trial.
    Wessels H, von Richter O, Velinova M, Höfler J, Chamberlain P, Kromminga A, Lehnick D, Roth K.
    Expert Opin Biol Ther; 2023 Mar 01; 23(12):1287-1297. PubMed ID: 38044885
    [Abstract] [Full Text] [Related]

  • 3. Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab.
    Selmaj K, Roth K, Höfler J, Vitzithum K, Derlacz R, von Richter O, Hornuss C, Poetzl J, Singer B, Jacobs L.
    BioDrugs; 2024 Nov 01; 38(6):755-767. PubMed ID: 39343860
    [Abstract] [Full Text] [Related]

  • 4. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial.
    Foley JF, Defer G, Ryerson LZ, Cohen JA, Arnold DL, Butzkueven H, Cutter G, Giovannoni G, Killestein J, Wiendl H, Smirnakis K, Xiao S, Kong G, Kuhelj R, Campbell N, NOVA study investigators.
    Lancet Neurol; 2022 Jul 01; 21(7):608-619. PubMed ID: 35483387
    [Abstract] [Full Text] [Related]

  • 5. PB006: A Natalizumab Biosimilar.
    Shirley M.
    Clin Drug Investig; 2024 May 01; 44(5):367-370. PubMed ID: 38683493
    [Abstract] [Full Text] [Related]

  • 6. Natalizumab for relapsing remitting multiple sclerosis.
    Pucci E, Giuliani G, Solari A, Simi S, Minozzi S, Di Pietrantonj C, Galea I.
    Cochrane Database Syst Rev; 2011 Oct 05; (10):CD007621. PubMed ID: 21975773
    [Abstract] [Full Text] [Related]

  • 7. Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial.
    Gobbi C, Meier DS, Cotton F, Sintzel M, Leppert D, Guttmann CR, Zecca C.
    BMC Neurol; 2013 Aug 02; 13():101. PubMed ID: 23915113
    [Abstract] [Full Text] [Related]

  • 8. Long-term effect of natalizumab in patients with RRMS: TYSTEN cohort.
    Bigaut K, Fabacher T, Kremer L, Ongagna JC, Kwiatkowski A, Sellal F, Ferriby D, Courtois S, Vermersch P, Collongues N, Zéphir H, De Seze J, Outteryck O.
    Mult Scler; 2021 Apr 02; 27(5):729-741. PubMed ID: 32643521
    [Abstract] [Full Text] [Related]

  • 9. Efficacy, safety, and pharmacokinetics of natalizumab in Japanese multiple sclerosis patients: A double-blind, randomized controlled trial and open-label pharmacokinetic study.
    Saida T, Kira JI, Kishida S, Yamamura T, Sudo Y, Ogiwara K, Tibung JT, Lucas N, Subramanyam M, Natalizumab Trial Principal Investigators.
    Mult Scler Relat Disord; 2017 Jan 02; 11():25-31. PubMed ID: 28104251
    [Abstract] [Full Text] [Related]

  • 10. Prevention of rebound effect after natalizumab withdrawal in multiple sclerosis. Study of two high-dose methylprednisolone schedules.
    Fuentes-Rumí L, Hernández-Clares R, Carreón-Guarnizo E, Valero-López G, Iniesta-Martinez F, Cabrera-Maqueda JM, León-Hernández A, Zamarro-Parra J, Morales-Ortiz A, Meca-Lallana JE.
    Mult Scler Relat Disord; 2020 Sep 02; 44():102311. PubMed ID: 32593958
    [Abstract] [Full Text] [Related]

  • 11. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ, Figgitt DP.
    CNS Drugs; 2004 Sep 02; 18(6):379-96. PubMed ID: 15089110
    [Abstract] [Full Text] [Related]

  • 12. Rituximab for relapsing-remitting multiple sclerosis.
    He D, Guo R, Zhang F, Zhang C, Dong S, Zhou H.
    Cochrane Database Syst Rev; 2013 Dec 06; (12):CD009130. PubMed ID: 24310855
    [Abstract] [Full Text] [Related]

  • 13. Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE.
    Perumal J, Fox RJ, Balabanov R, Balcer LJ, Galetta S, Makh S, Santra S, Hotermans C, Lee L.
    BMC Neurol; 2019 Jun 08; 19(1):116. PubMed ID: 31176355
    [Abstract] [Full Text] [Related]

  • 14. Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study.
    Perumal J, Balabanov R, Su R, Chang R, Balcer L, Galetta S, Campagnolo DI, Avila R, Lee L, Rutledge D, Fox RJ.
    Adv Ther; 2021 Jul 08; 38(7):3724-3742. PubMed ID: 34014549
    [Abstract] [Full Text] [Related]

  • 15. Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial.
    Kappos L, Fox RJ, Burcklen M, Freedman MS, Havrdová EK, Hennessy B, Hohlfeld R, Lublin F, Montalban X, Pozzilli C, Scherz T, D'Ambrosio D, Linscheid P, Vaclavkova A, Pirozek-Lawniczek M, Kracker H, Sprenger T.
    JAMA Neurol; 2021 May 01; 78(5):558-567. PubMed ID: 33779698
    [Abstract] [Full Text] [Related]

  • 16. Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis.
    Arnold DL, Calabresi PA, Kieseier BC, Sheikh SI, Deykin A, Zhu Y, Liu S, You X, Sperling B, Hung S.
    BMC Neurol; 2014 Dec 31; 14():240. PubMed ID: 25551571
    [Abstract] [Full Text] [Related]

  • 17. Ocrelizumab for multiple sclerosis.
    Lin M, Zhang J, Zhang Y, Luo J, Shi S.
    Cochrane Database Syst Rev; 2022 May 18; 5(5):CD013247. PubMed ID: 35583174
    [Abstract] [Full Text] [Related]

  • 18. Effectiveness and Adverse Events of Use of Natalizumab in a Brazilian Cohort of Patients With Multiple Sclerosis.
    Deslandes MQ, Alves PT, Alvarenga MP, Lessa VCC, Camargo S, Alvarenga RMP, Vasconcelos CC.
    Clin Ther; 2020 Jul 18; 42(7):1292-1301. PubMed ID: 32593474
    [Abstract] [Full Text] [Related]

  • 19. A multicenter, non-interventional study to evaluate the disease activity in Multiple Sclerosis after withdrawal of Natalizumab in Portugal.
    Ladeira F, Braz L, Salgado P, Vaz S, Leitão L, Félix C, Correia AS, Silva AMD, Salgado V, Ferreira F, Vale J, Sá MJ, Capela C.
    Clin Neurol Neurosurg; 2019 Sep 18; 184():105390. PubMed ID: 31306895
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of peginterferon beta-1a compared to interferon beta-1a in relapsing remitting multiple sclerosis patients: A phase 3, randomized, non-inferiority clinical trial (PEGINTEGRITY).
    Shaygannejad V, Ashtari F, Saeidi M, Beladi Moghadam N, Ghalyanchi Langroodi H, Baghbanian SM, Abolfazli R, Ghiasian M, Ayromlou H, Asadollahzadeh E, Sabzvari A, Kafi H, Azimi Saeen A.
    Mult Scler Relat Disord; 2024 Oct 18; 90():105839. PubMed ID: 39217809
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.